Executive Director, Global Scientific Communications Lead, Hematology

## Executive Director, Global Scientific Communications Lead, HematologyApply: Full Remote: New York, New York, USA: Full time: Posted 6 Days Ago: JR100066**Company:**0750 Stemline Therapeutics Inc**Contract Type:**Permanent **Join us in shaping the future of Menarini - with passion, integrity, and a deep commitment to people.**About Menarini Group - Menarini is a leading international biopharmaceutical company committed to advancing health through innovation, research, and quality. For more than 135 years, we have worked to improve patients’ lives across a broad range of therapeutic areas through our dedication to science, integrity, and care for people. With a strong foundation in scientific excellence and a purpose-driven culture, Menarini offers diverse career opportunities for professionals eager to make a meaningful impact on global health.**Position Title: Executive Director, Global Scientific Communications Lead - Hematology** **Reports to: Vice President, Global Medical Affairs Hematology** **Overview**:This is a great opportunity for a strategic Scientific Communications Leader to lead the planning and execution of strategic scientific communications and publication plans for Stemline Hematology pipeline and marketed products. Global lead for scientific communications across the hematology pipeline and product portfolio. This role requires an experienced, hands-on expert who will both drive the strategic vision and actively execute publication planning, publication development, literature surveillance, and the development of internal training materials and external scientific tools. **Responsibilities**: * **Publications** + Coordinate cross-functionally to build consensus and drive alignment on the global publication strategy and tactical publication plan. + Lead the development of high-impact medical and scientific publications (including abstracts, posters, oral presentations, and manuscripts)**,** collaborating closely with internal and external stakeholders to meet timeline milestones. Critically review, revise, and enhance draft publications to ensure scientific quality, alignment with asset-specific messaging, and adherence to established lexicons. + Recommend target journals and congresses based on industry experience and a strong understanding of the evolving hematology publication landscape. + Critically evaluate clinical trial data and published literature to ensure all materials accurately, ethically, and transparently convey scientific evidence. + Develop data analysis plans to support secondary publications. + Operate in accordance with all corporate SOPs and promote the adoption of working standards consistent with Good Publication Practice (GPP) guidelines. + Maintain an understanding of the evolving publication landscape through active engagement with and participation in professional societies (e.g., ISMPP).* **Literature Surveillance, Tools and Training** + Lead real-time competitive intelligence efforts around key hematology congresses, coordinate alignment on search criteria and abstract selection with the core team, manage vendor drafting, and critically review, revise, and enhance summaries and insights pre-, during-, and post-congress. + Lead monthly literature surveillance including development of data summaries and integration of insights. + Critically review, revise, and enhance data summaries and insights to ensure scientific quality, alignment with asset-specific messaging, and adherence to the established lexicons. + Lead the creation and delivery of monthly, literature-based educational sessions for the Medical team. + Lead the development of comprehensive internal training materials for MSL certification, direct vendor execution, and drive content completion through rigorous updates and critical review. + Lead the creation of literature-based, external-facing scientific tools for MSL use including managing vendor development and conducting final critical reviews to ensure scientific accuracy. + Provide direct leadership, mentorship, and professional development to the Senior Manager, Publication Operations, ensuring seamless oversight of publication logistics, tracking systems, and operational workflows. + Manage publication, scientific communication and writing vendors as needed. Manage publication and scientific communication budget. Collaborate with other members of the Medical Affairs organization in support of their functional area deliverables. + Attend scientific conferences to ensure accurate and appropriate presentation of Stemline’s scientific evidence, enhance therapeutic knowledge, and contribute to execution of Medical Affairs conference deliverables. Support process improvement initiatives. **Qualifications:** * Doctorate level degree (PharmD, MD, PhD) with at least ten years of related experience.* Experience in pharmaceutical/biotech industry is required.* Oncology/hematology experience highly preferred.* Significant experience with publication development, writing, and management for medical publications is required.* Experience executing strategically and tactically working successfully with cross-functional, dynamic teams.* Experience with clinical trial design, interpretation of scientific data, and communication via clinical and medical affairs channels.* Understanding of the pharmaceutical/biotech industry, particularly medical publishing, and proven adherence to related regulations, guidelines, standards, and practices including GPP and ICMJE.* Familiarity with the principles of healthcare compliance.* Demonstrated ability to lead initiatives, manage projects, and work cross-functionally.* Skilled medical writer.* Self-motivated, organized, problem-solving, solution-oriented, collaborative team player.* Able to act independently, with strong leadership skills, and effectively manage direct reports, cross-functional teams, and projects for multiple initiatives in a fast-paced environment yet remain flexible in response to changing needs and competing demands.* Strong written and verbal communication skills, with a proven ability to translate complex medical and scientific data for a variety of audiences.**Please note: this position is classified as a corporate office position. In accordance with the New York employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.** *Please note: This position is classified as a corporate office position. In accordance with the New York state employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.**Base Salary Range of $260,000 - 362,000. Menarini Stemline offers generous compensation and benefits packages, including, Fidelity 401(k) (with company match), PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.**Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions. To request an accommodation, please contact View email address on click.appcast.io. com prior to your interview.* **Base Salary Range of:**260000 Menarini Stemline offers generous compensation and benefits packages, including Fidelity 401(k) (with company match), Healthcare insurance, Company-paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs. Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions. **The Company** Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents. Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF). Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines. Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023. Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods. Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey. In 2022, the company launched the CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management. It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline's Oncology business. #J-18808-Ljbffr